Antibody Contract Manufacturing Market Report 2025

The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $14.8 billion in 2024 to $16.84 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to increased demand for monoclonal antibodies, shift towards personalized medicine, cost optimization, stringent regulatory requirements, globalization of biologics.

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.86 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing r&d spending, expansion of bispecific and multispecific antibodies, rise of antibody-drug conjugates (adcs), increasing healthcare infrastructure, growing government initiatives. Major trends in the forecast period include digitalization and data analytics, advanced upstream technologies, novel downstream processing techniques, sustainability initiatives, contract development and manufacturing integration (CDMO).

The anticipated rise in the number of clinical trials is poised to drive the growth of the antibody contract manufacturing market in the coming years. Clinical trials, which involve research studies conducted with human participants to assess the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are witnessing an increase in the utilization of antibody-based therapeutics or diagnostics. This surge accentuates the demand for high-quality antibodies to ensure a timely and compliant supply for clinical trials. According to ClinicalTrials.gov's May 2023 data, the number of registered clinical trial studies globally increased from 399,499 in 2022 to 437,533 in 2023, with around 53% of these studies registered outside the United States. Hence, the growing number of clinical trials is a key driver behind the expansion of the antibody contract manufacturing market.

The expected growth in the prevalence of chronic diseases is set to propel the antibody contract manufacturing market forward. Chronic diseases, characterized by their persistent and often progressive nature, require therapeutic antibodies for treatment. Antibody contract manufacturing plays a vital role in producing these therapeutic antibodies designed to target specific proteins or cells associated with chronic conditions, offering targeted and personalized treatment. With the U.S. population aged 50 and above projected to increase by 61.11% by 2050, and the prevalence of chronic diseases in this demographic nearly doubling, from 71.522 million in 2020 to an estimated 142.66 million by 2050, the demand for antibody contract manufacturing is expected to rise significantly.

Major companies in the antibody contract manufacturing market are concentrating on innovations such as single-use technology (SUT), which minimizes cross-contamination risks and reduces operational costs. SUT refers to disposable components and systems utilized in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, launched the Mobius ADC Reactor, aimed at enhancing the manufacturing of antibody-drug conjugates. This new single-use reactor significantly improves production efficiency by 70% compared to traditional stainless steel or glass methods. Its single-use design reduces cross-contamination risks and operational costs, enabling faster turnaround times. Additionally, advanced film technology enhances bag strength and leak resistance, ensuring the integrity of highly potent active pharmaceutical ingredients. This innovation supports biopharmaceutical companies in producing essential therapies more safely and efficiently.

Major companies in the antibody contract manufacturing market are focused on developing innovative solutions such as bispecific antibody platforms. These platforms play a pivotal role in the development of bispecific antibodies, utilizing scientific and technological approaches to create specialized antibodies. For instance, in September 2022, Samsung Biologics launched 'S-DUAL' and 'DEVELOPICK.' S-DUAL, a high-yield bispecific antibody platform, boasts a remarkable 99% success rate in chain pairing, optimizing manufacturing ease and achieving elevated titer and purity. DEVELOPICK, a rapid accessibility platform, enables the screening of molecules in early development, identifying candidates with optimal potential for progression to Investigational New Drug (IND) and Biological License Application (BLA). This comprehensive risk assessment platform empowers clients to evaluate drug candidates efficiently.

In April 2022, Asahi Kasei Medical Co., Ltd. acquired Bionova Scientific LLC for an undisclosed amount. This strategic acquisition expanded Asahi Kasei Medical's bioprocess business by incorporating a biopharmaceutical CDMO (contract development and manufacturing organization). Bionova Scientific LLC, a U.S.-based CDMO, specializes in developing and manufacturing recombinant protein products, including antibodies.

Major companies operating in the antibody contract manufacturing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.

North America was the largest region in the antibody contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Antibody contract manufacturing involves the outsourcing of antibody production and manufacturing to specialized contract manufacturing organizations (CMOs). These organizations possess the necessary expertise, infrastructure, and resources required for the manufacturing of antibodies on behalf of pharmaceutical and biotechnology companies.

The primary products of antibody contract manufacturing include monoclonal antibodies, polyclonal antibodies, and other antibody-related products. Monoclonal antibodies (mAbs) are specifically designed to target a particular antigen, and antibody contract manufacturing plays a crucial role in producing monoclonal antibodies on a large scale. This ensures consistent quality and quantity, meeting the demands for therapeutic or diagnostic applications. These antibodies are derived from sources such as mammals and microbes, and the manufacturing processes span preclinical, clinical, and commercial scales of operation. The end users of these antibody products include biopharmaceutical companies, research laboratories, and other entities.

The antibody contract manufacturing research report is one of a series of new reports that provides antibody contract manufacturing market statistics, including the antibody contract manufacturing industry's global market size, regional shares, competitors with a antibody contract manufacturing market share, detailed antibody contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the antibody contract manufacturing industry. This antibody contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.